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ABSTRACT




The macrobead is a form of a biohybrid artificial pancreas (BAP), which is being
developed to treat type 1 diabetes [1]. A hypothetical human transplant would require
125 rat equivalent macrobeads. For intraperitoneal transplantation a mode of delivery
that allows the placement of several hundred macrobeads into a basket or pouch type
device is required.
In this study, four commercially available materials were studied as possible
candidates for creating a pouch. These materials are polyvinyl chloride acrylic copolymer
(PVC), polyethersulfone (PES), polyvinylidenedifluoride (PVDF), and
polytetrafluorethylene (PTF.E). Tubular pouches of each material were designed. They
then underwent in vivo biocompatibility and in-vitro permeability examinations.
Biocompatibility was evaluated by semi-quantitatively analyzing the degree of tissue
reaction on the materials surface. Permeability to insulin was quantitatively determined
by assaying samples of medium in which pouches containing functioning macrobeads
were cultured.
Based on the results two materials PES and PVDF appear suitable for creating a
pouch to hold a large number of macrobeads. Additionally, parameters such as pore size
and shape of pouch are also critical and require attention.
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CHAPTER 1
INTRODUCTION
Insulin dependent diabetes mellitus (type 1, IDDM), an auto-immune disease
occurring in individuals of all ages, affects approximately 1 million people in the
United States [2]. These individuals require daily multiple insulin injections [3].
Advances during the last decade increasingly indicate a multifactorial etiology of the
disease [4]. The various forms of diabetes and its complications represent the third
leading cause of death in the United States. It is estimated that diabetes places a
yearly 92 billion dollar strain on America's health care system [5].
1.1 Pathophysiology of Diabetes
In type 1 diabetes, as a result of a cellular/humoral autoimmune attack, the insulin
secreting abilities of the beta cells, in the Islets of Langerhans, are destroyed entirely
[6-10]. Insulin is the primary hormone which controls the storage and metabolism of
ingested foods in the liver, muscle, and fat tissue of the body. The result of insulin
deficiency is an increase in blood glucose concentration. This hyperglycemic
condition, when maintained for a substantial period of time, directly relates to





The basic treatment for type 1 diabetes has not changed since insulin became
available in the 1920s [8]. It involves the administration of exogenous insulin via
injection devices and/or implantable insulin secreting pumps. Attempts have also
been made to design aerosolized nasal and oral insulin sprays [11]. Daily injection of
insulin requires the burdensome tasks of continuously monitoring blood glucose
levels and then calculating the proper dosages for insulin administration. Because
this method can be imprecise, the risk of overdosing causing hypoglycemia, or
underdosing leading to ketoacidosis is ever-present.
Additionally, although conventional exogenous insulin therapy reduces the
incidence of acute diabetic comas, the life expectancy of IDDM individuals continues
to remain well below that of the general population [8]. Conventional insulin therapy
fails to provide glucose maintenance adequate enough to prevent onset of the long-
term complications associated with diabetes [12].
Recent research suggests that many of the complications of diabetes may be
avoided or significantly reduced by a more precise and continuous control of blood
glucose levels [13,14,15]. Despite intensive work on several exogenous insulin




One alternative method for treating type 1 diabetes involves transplantation of whole
or segmented portions of the pancreas. This method is attractive physiologically
because it will maintain blood glucose in a manner similar to that of a normal
individual.
Although pancreatic transplantation would appear to be an ideal method of
therapy for insulin dependent diabetics, there are a number of limitations that hinder
its large scale utilization. Aside from the initial obstacle of human organ
procurement, whole pancreas transplantations are major surgical procedures with
high costs. Additionally, transplanted graft survival is dependent upon the
administration of life long immunosuppressive drugs. Because immunosuppressive
drugs have the potential to cause serious side effects, it usage for protecting whole
pancreas transplantations in young "healthy" diabetics would be counterproductive.
Currently, most pancreatic transplantations are performed in conjunction with kidney
transplantations, which themselves necessitate immunosuppressive therapy [16].
For "healthy" diabetics, transplantations of isolated islets of Langerhans may
prove to be the most desirable method of treatment for preventing the onset of long-
term complications [17,18]. Islet transplantation requires only minor surgery and thus
incurs low risks especially when compared to whole pancreas transplantations.
The transplantation of isolated islets of Langerhans, although promising, is
hindered by problems of human donor procurement, isolation and purification
techniques, immune rejection, and in-vivo function [17,18,19]. In addition, evidence
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of the auto-immune nature of diabetes indicates that unprotected islet transplants will
be destroyed by the same sequence of events that destroyed the original pancreas [16].
Auto-immune destruction of transplanted islets might be prevented by
purposefully implanting islets whose tissue-typing antigens do not resemble those of
the host's original islets [18,20]. Alternatively, many investigators are exploring
ways to prevent rejection by encapsulating donor islets into semi-permeable
membranes [11,12]. As a result of this latter research, the Biohybrid Artificial
Pancreas (BAP) has been developed [18].
1.4 Biohybrid Artificial Pancreas
The BAP consists of insulin secreting islet cells encapsulated by a semi-permeable
membrane. The membrane allows the passage of low molecular weight molecules
such as glucose, insulin, and nutrients, while it simultaneously protects the islets from
rejection by preventing the passage of T-cells or antibody cells of the host immune
system [18,20].
At their most general level, BAPs can be categorized as either intravascular or
extravascular systems. Although these systems differ greatly in their modes of
operation, the basic principle in both remains the same. In BAPs, glucose diffuses
through the membrane to the islets, thereby inducing insulin secretion. The insulin, in
turn, builds up in the chamber and diffuses through the membrane into the blood
supply.
Immuno-isolation systems have several potential advantages over other insulin
delivery systems. First, since beta cells in isolated islets of Langerhans maintain their
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normal response to glucose and other secretagogues, insulin (and other islet
hormones) released from the device can be controlled in a manner similar to a normal
individual [21,22,23]. Feedback in blood glucose concentrations as well as
responsiveness to changes in the concentrations of other stimuli such as amino acids,
fats, and gastric inhibitory polypeptides will help determine the appropriate amount of
insulin release. Second, because experimental evidence shows that through isolation
and encapsulation techniques, it is possible, without using any immunosuppressive
therapy, to prevent rejection of allogenic and xenogenic transplanted islet tissue an
unlimited supply of non-human islets become available for transplantations
[18,24,25].
The work of several investigative teams has established the validity of the
principles upon which immuno-isolation is based. Immune protection via membrane
separation has been shown to be a viable concept in general, and with islets in
particular [26,27]. Islets have been shown to maintain insulin release during culture
in hollow fibers and in microcapsules [26,27,28]. Extravascular devices have
remained viable in vivo for greater than 250 days [29,30]. Intravascular shell devices
have remained patent for up to 267 days in pancreatomized dogs [29].
In both types of devices, however, continued success is prevented because of
complications which arise as a result of their specific designs. Many publications
describe how the attachment of an intravascular device to a blood vessel makes the
blood more prone to clotting [31]. Discontinuities in blood flow are the major
reasons for this clotting. In extravascular devices, the limiting factor arises as a result
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of tissue-material interfaces between the device membrane and natural body tissue.
Extravascular devices, such as microbeads made from alginate-poly-L -lysine [32],
that are transplanted into the peritoneal cavity have a tendency to cause a tissue
inflammatory reaction. This reaction results in a layer of fibrous tissue, around the
device, ranging from 50 to 100um thick [30]. As a result the diffusion distance from
the islets to the blood circulation is extended beyond the point effective for proper
metabolic exchange [31].
In addition to tissue inflammatory reactions caused by certain materials, it has
been shown that certain geometries of a BAP may also induce the tissue inflammatory
cascade. In 1982, Woodward examined the influence of a diffusion chamber's
geometry on the occurrence of fibrosis [33]. He showed that a disk-shaped chamber
induced a zone of collagen-rich connective tissue around the implant. Other
investigations, to assess the potential of tubular devices as BAPs, have been
conducted [34]. These studies showed that wider-bore tubular membranes were better
able to resist adhesions and fibrous formations [34]. Mitsuo has transplanted tubes
4cm in length and 2mm in inner diameter into the peritoneal cavity of diabetic rats
[35]. One month after implantation the tube was examined and found to have
extremely thin fibrous tissue deposits on the surface. Moreover, the tube scarcely
adhered to surrounding tissue and was easily retrieved.
Altman [36] stresses the importance of eliminating any dead space within the
structure, while simultaneously maximizing the diffusion surface areas. Additionally,
Ward [37] emphasizes the need for smoothness on the materials outer surface.
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1.5 The Macrobead
Recently, the islet purification laboratory of The Rogosin Institute, reported the
development of a retrievable, replaceable, biohybrid artificial pancreas, the
macrobead, which maintains blood glucose levels in a manner similar to a normal
functioning pancreas [1]. In vitro studies showed that five macrobeads, containing
1000 Wistar Furth rat islets, encapsulated in a collagen-agarose matrix, were able to
secrete 1.8 to 2.4 units of insulin in 24 hours. Additionally, insulin released from the
cultured macrobeads remained constant for at least 154 days. In vivo studies, in
which a macrobead was implanted into the peritoneal cavities of chemically induced
diabetic B6AF1 mice showed a return to euglycemia within 24 hours. Thereafter,
euglycemia was maintained for more than 100 days. Recipient mice had normal
responses to glucose tolerance tests, indicating that the islets in the macrobead were
functioning as they would in an intact pancreas. The macrobeads' biocompatibility
was demonstrated by the absence of any fibrosis or adhesions to peritoneal tissues.
Macrobeads, which were removed from the first recipient after 100 days and stored in
vitro, were able to maintain euglycemia when retransplanted into other diabetic mice.
These results indicate that collagen-agarose macrobeads (6000-8000pm in
diameter) are capable of maintaining long term euglycemia in diabetic recipients.
Therefore, macrobeads appear suitable for clinical human xeno-islet transplantations.
However, before the macrobeads become the method of choice for treating diabetes,
its mode of implantation into the peritoneal cavity requires extensive investigation.
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1.6 Mode of Delivery-Scope of Thesis
An average human requires approximately 60 units of insulin per day [30]. Thus a
hypothetical human macrobead transplantation would require a minimum of 125 rat
equivalent macrobeads (each containing 1000 Wistar Furth rat islets). If these
macrobeads are transplanted freely into the peritoneal cavity, there is a danger of their
entrapment within an organ. Another complication may occur if the beads break and
produce a tissue reaction, resulting in possible adhesions. Finally, when replacement
of macrobeads is required, free beads in the peritoneal cavity would be very difficult
to retrieve. To overcome these problems, a mode of delivery that allows the
placement of several hundred macrobeads into a basket or pouch type device would
be desired. Such a device would improve the efficiency of transplantations into larger
animals and eventually humans by maintaining all the macrobeads at the site of
implantation.
In creating a pouch, compliance with three important criteria is required.
First, the material must be permeable to glucose, insulin, and amino acids. Second,
the material must be completely biocompatible. Third, the material must have
sufficient strength to hold a large number of macrobeads. Immune protection is not a
required characteristic because the macrobeads, themselves, are immuno protective.
CHAPTER 2
METHODS
2.1 Commercially Available Materials
Four commercially available synthetic materials have been identified as possible
candidates for creating a pouch within the peritoneal cavity. These materials are: 1)
Polyvinyl chloride acrylic copolymer, 2) Polyethersulfone, 3) Polyvinylidene-
difluoride, and 4) Polytetrafluorethylene (PTFE-Teflon).
Polyvinyl chloride acrylic copolymer (PVC) 
The use of acrylic copolymers as a selectively-permeable membrane in a BAP is well
documented [30,38,39]. Tubular acrylic copolymer chambers, using xenogenic islet
tissues, have been implanted into the peritoneal cavity of spontaneously diabetic rats
and pancreactomized diabetic dogs. Graft survival periods range from 60 to 270 days
[31]. Upon removal, examination of the BAPs showed very slight fibrosis (from one
cell layer to <50um thick).
The Amicon Division of W.R. Grace and Co. manufactures a polyvinyl
chloride acrylic copolymer membrane (Amicon XM-50). This membrane is attached
to an inert glossy surface which improves its handling capabilities. If this inert
coating also increases the membrane's biocompatibility then the Amicon copolymer




In January 1994, Takagi and Iwata reported a novel microbead using agarose and
polystyrene sulfonic acid [40]. The surface of the macrobead was also coated with
chondroitin sulfate to enhance the microbead's biocompatibility. When 1,000
hamster islets, encapsulated into microbeads, were transplanted into the peritoneal
cavity of STZ-induced diabetic mice, normoglycemia was achieved and maintained
for more than 100 days.
Gelman Sciences manufactures polyethersulfone membranes which have high
mechanical strength and easy to handle characteristics. Additionally these membranes
comply with U.S.P. Class VI-121 plastics tests for biosafety, and have passed
cytotoxicity and hemolysis testing. These physiochemical properties of
polyehtersulfone indicate that this material, too, may be suitable for encasing large
numbers of macrobeads.
Polyvinylidenedifluoride (PVDF) 
In 1991, Makino reported a self-regulated insulin delivery system [41]. The device
consisted of chemically bound insulin, encapsulated into microcapsules. The
microcapsules were then placed into a Durapore polyvinylidenedifluoride membrane
pouch. In vitro studies, in which an influx of glucose was administered and an efflux
of insulin was measured, showed that this device was able to respond, with no
significant lag time, to a glucose challenge.
Millipore manufactures a modified hydrophilic polyvinylidenedifluoride
membrane in which the physiochemical properties include: a thickness of 125um, a
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porosity of 70% and most importantly, a protein binding ability of only 4ug/cm 2 .
Additionally, this membrane has a high degree of mechanical strength and so can be
folded and pleated without breaking. These properties make the modified
polyvinylidenedifluoride membrane an excellent candidate for an intraperitoneal
pouch.
Polytetrafluorethylene (PTFE) 
Polytetrafluorethylene (Teflon) is the most commonly used material for small
diameter artificial vascular grafts [42]. Teflon when transplanted into in vivo
systems, is able to maintain its surface integrity without causing any cell adhesions or
tissue reactions. Intravascular BAP devices using PTFE grafts in the form of an
arteriovenous shunt have been transplanted into diabetic dogs [43]. Device patency
has been maintained for 3.5 years while xenogenic graft function was maintained for
106 days [25].
The major concern in using PTFE membranes to design a pouch for peritoneal
macrobead transplantation is their hydrophobic characteristics. Most BAP
investigators agree that all membranes used in peritoneal transplantations should be
hydrophilic [44]. If Teflon's hydrophobicity can be overcome; e.g., by introducing
large pores to the membrane surface; while still maintaining it's biocompatible
properties, then it may be the material of choice.
Impra, a division of Gore-Tex, manufactures Teflon vascular grafts which
come in varying degrees of inner diameter and wall thickness.
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2.2 Design of a Delivery System
Designs of a peritoneal pouch, for the sole purpose of maintaining large numbers of
immunoprotective micro/macrobeads, have not been described. However, by
reviewing the existing literature on proposed micro/macroencapsulated bioartificial
pancreas designs, a great deal of information may be obtained [33,34,35,36,37].
Taking this information into account, it would appear that a pouch with a
tubular shape would be most desirable. Additionally, although contradicting the
requirements of surface smoothness, the efficiency of the macrobead-pouch system
may further be enhanced by creating large pores onto the membrane surface. Testing
of such a device may show greater responding ability when exposed to a glucose
challenge.
2.3 Experimental Procedure
All experiments were performed after the study design and procedures had been




The experimental design for creating a mode of delivery using commercially available
materials was composed of two phases. (Flowchart 2.1). In Phase I the materials
underwent in vivo biocompatibility examinations. In Phase II, the materials
underwent in vitro permeability examinations. The results of Phases I and II have




2.3.2 Phase I: In Vivo Transplantations
For in vivo studies, pouches were prepared by manipulating the membranes into
tubular shaped devices. In a few pouches (n=3-5), for each material, large pores were
introduced onto the membrane surface. This allowed us to determine whether the
diffusive transport of molecules can be increased without causing any detrimental
effect to the recipient. For each material, 6-10 normoglycemic Wistar Furth rats were
transplanted by freely dropping a single pouch into the peritoneal cavity.
Transplantation of 6 empty macrobeads into the peritoneal cavity of a single recipient
served as a control. To monitor post-surgical recovery, long-term physical condition,
and any possible toxic effects due to the materials after intraperitoneal transplantation
of pouches, each recipients body weight was determined on the day of surgery and
every fourth day after, until explantation of the pouches was performed. At 16 (n=3
for PVDF, PES, and PTFE) and 44 (n=7 for PVDF, PES, and PTFE, n=6 for PVC)
days post transplantation the implants were removed. The material's durability (i.e.
ability to hold a specific number of macrobeads without rupturing) was evaluated by
visually examining all retrieved pouches for physical defects. Each materials
biocompatibility (i.e. degree of tissue reaction) was semi-quantitatively evaluated by
determining the percent of surface area free of fibrosis.
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1. Preparation of pouches
For PVDF, PES, and PVC 10 rectangular sheets (5cm x 3cm) were cut.
PTFE comes as a tube with an inner diameter of 19mm. To prepare
pouches from PTFE, the tube was cut at 3cm intervals ten times.
For 3 pouches of each material, except PTFE where n=5, large pores
(4mm diameter) were created via a stationary hole punching device.
Using a cylindrical tube (10mm diameter) as a mold, PVDF, PES, and
PVC membranes were wrapped around into a tubular shape. The 3cm
edge was used to wrap around the mold. As a result, 10mm diameter,
5cm long cylindrical pouches were created.
MF cement glue (Millipore, Bedford, MA) was used to seal the
materials along the 5cm length of the tube (not required for PTFE).
MF cement glue was then added to close one end of the tube.
All the pouches were then sterilized by autoclaving for 20 minutes at
120 °C.
2. Preparation of empty macrobeads [1]
A 5% Agarose solution using Type XII Agarose (Sigma, St. Louis,
MO), 1% antibiotic-antimycotic (Gibco, Grand Island, NY) and MEM
medium (Gibco) was prepared.
The solution was maintained in a 60 °C water bath.
One hundred microliters of solution was transferred as a single drop
into sterile mineral oil at room temperature.
After 1 minute, the now smooth, semisolid macrobead was transferred
to RPMI Antibiotic medium (RPMI, 1% antibiotic-antimycotic
[Gibco] at 37 °C.
To remove any residual oil, the macrobead was washed 5 times with
antibiotic RPMI medium.
The empty macrobeads were stored in an incubator which maintains a
condition of 37 °C, with a humidified atmosphere of air and 5% CO2.
3. Filling pouches with macrobeads
Pouches were soaked in antibiotic RPMI medium at 37 °C for 24
hours.
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Using a Teflon coated spatula, 6 macrobeads were placed into each
pouch.
The remaining open end was then sealed via MF cement glue.
The macrobead containing pouches were then incubated in complete
medium at 37 °C until the day of transplantation.
4. Transplantation of pouches
All surgical tools were sterilized by autoclaving and all surfaces near
the transplantation site were wiped thoroughly with 70% ethanol.
Each recipient was anesthetized using a 50mg/kg intraperitoneal
injection of pentobarbitol Na, or a combination of 20mg/kg Ketamine
and 4mg/kg Xylazine. The ventral side of the animal was shaven to
remove outer fur coating. Using an alcohol pad, the ventral surface
was wiped to remove any remaining hair fibers. Betadine was then
applied, to clean the exposed skin.
Beginning near the bottom of the peritoneal cavity, a mid-line incision
through the peritoneal wall was made. The incision was carried for
5cm towards the top of the peritoneal cavity. For the control, only a
2cm cut is required.
The pouches were freely dropped into the peritoneal cavity. For the
control, macrobeads were similarly dropped into the peritoneal cavity.
A two layer closure, using an absorbable suture, was performed.
5. Evaluation of pouches
For all transplants, the animal's body weights were measured on the
day of surgery and every fourth day after until explantation of the
pouches was performed.
At the end of the desired incubation periods (16 days and 44 days) all
animals were sacrificed.
Implants and surrounding tissues were retrieved and then fixed in 4%
buffered formalin.
Each membrane pouch and the beads within. were visually examined
for physical defects (e.g. tears).
18
For assessing biocompatibility, a semi-quantitative method for
determining the percent of surface area which is free of any fibrosis
was used. To simplify calculations, all pouches were flattened into a
rectangular shape. Total surface area of the pouch was then calculated
by the formula: (2 x length x width). Surface area which is free of
fibrosis was then calculated. The areas free of fibrosis were simplified
into rectangular shapes. The area of the rectangles were calculated by
multiplying length x width. For the pouches with large pores, the area
of each pore was taken into account by first determining whether the
pore is open or closed. If a pore was open, then its surface area was
added to the amount of surface area free of fibrosis. The area of each
pore was calculated by using the formula for determining the area of a
circle (nr2 where r equals 2mm, the radius of the pores). The percent
of surface area free of fibrosis was then calculated by the formula:
%Surface area surface area free of fibrosis x 100
free of fibrosis = 	 total surface area
2.3.3 Phase II: In Vitro Permeability
In Phase II each material's permeability to insulin was quantitatively determined by
assaying samples of medium in which pouches containing functioning macrobeads
were cultured. Insulin release in a 24hr time period was calculated for 12 samples of
macrobeads (3 for each material). The macrobeads of each sample were then placed
into pouches and assayed again to determine the amount of insulin release.
1.Preparation of pouches
The same procedure as described in Section 2.3.2 Step 1, was used,
except no large pores were introduced onto the pouch surface.
2. Procurement of functioning macrobeads
Porcine insulin secreting macrobeads were obtained from The Rogosin
Institute's Islet Purification Laboratory.
3. Assessing insulin release from macrobeads
Twelve dishes each containing a specific number of porcine insulin
secreting macrobeads were cultured in 50m1 of RPMI medium with
25mM HEPES [Gibco, Grand Island, NY] 10% heat-inactivated
porcine serum [Cellgro, VA], and antibiotic-antimycotic solution
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lm1/100m1 [Gibco] (hereinafter referred to as complete medium) in a
humidified atmosphere of 5% CO2 and 37 °C. The medium in the
dishes was changed once a week.
To determine the amount of insulin release in a 24 hour time period,
the medium in each dish was changed an additional time. After 24
hours, a 2m1 sample of medium was collected from each dish and
immediately frozen and stored at -20 °C until radioimmunoassay was
performed.
Insulin release in the medium was determined by radioimmunoassay
(RIA) using a kit for measuring porcine insulin [Linco Research Inc.,
St. Charles MO]. (Appendix A).
4. Encasing functioning macrobeads into a pouch
All pouches were soaked in antibiotic RPMI medium at 37 °C for 24
hours.
To eliminate the possibility of any dead space (e.g. air bubbles)
existing within the pouch, each pouch was completely filled with 0.5%
agarose solution. Macrobeads were then placed inside the pouch and
suspended in the 0.5% agarose solution.
Using a Teflon spatula, all the macrobeads in a dish were placed into a
pouch containing 0.5% agarose solution. As each bead was dropped,
an equivalent volume of 0.5% agarose was displaced.
After placement of the final macrobead, the open end of the pouch was
plugged using 5% agarose.
Once the agarose plug solidified, the pouch was incubated in 80m1
(100m1 for PTFE) of complete medium.
For each of the four materials, three pouches were filled with
functioning macrobeads and assayed for insulin release.
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5. Evaluation of insulin release from the pouches
To determine the amount of insulin release in a 24 hour time period,
the medium in each dish was changed. After 24 hours, a 2m1 sample of
medium was collected from each dish and immediately frozen and
stored at -20 C° until radioummunoassay was performed. This
procedure was performed on 1, 7, and 16 days post-encasement.
Insulin release in the medium was determined by MA.
CHAPTER 3
RESULTS
3.1 Clinical Evaluations after Transplantation
Figure 3.1 shows the mean post-surgical weight gain of animals over a period of
44 days for transplants of each material. Individual data for each transplanted
animal is listed in Appendix C.
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of each material. Results are expressed as the
percentage of the weight measured on the day of
surgery (day 0). Sample size: PVC (n=6), PES(n=4),
PVDF(n=7), PTFE(n=6), CON(n=1).
Figure 3.1 Post Surgical Weight Recovery
Except for two recipients, the control and an animal receiving a PVC
membrane pouch, all transplanted animals experienced weight loss at 4 days post
surgery. Transplants with PVDF membrane pouches experienced an average
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weight loss of 16.8±2.7 (±SEM) grams. Similarly, recipients of PTFE, PVC, and
PES membrane pouches experienced average weight losses of 18.8±4.2, 19.0±8.4,
and 23.4±3.25 grams, respectively. At four days post surgery the control (i.e.
intraperitoneal transplantation of 6 empty macrobeads) had full recovery and in
fact had gained 5.1 grams. The transplants who received macrobeads enclosed in
pouches showed delayed recovery. By the 12th day of recovery, 21 of 23
transplanted animals regained their pre-surgery body weight. They then
continued to gain weight until 44 days post-surgery, at which point the pouches
were removed for evaluation.
3.2 Effects of 4mm Pore Size
Table 3.1 compares the results obtained from implanting pouches with large
(4mm) pores to the results obtained from implanting pouches which did not have
large pores. Of 14 transplants with large pores, 6 recipients died within 8 days of
implantation. In tranplants without large pores all animals survived (24/24). With
pouches having large pores intestinal obstruction was observed and was probably
the cause of death in all six cases. The 4mm pores allowed the intestines to enter
and entangle within the pouch. Figure 3.2 visually describes this phenomena.
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3.3 Durability of Pouches
Examination of the retrieved pouches indicate that all four materials are capable
of withstanding the forces encountered in the peritoneal cavity. There were no
tears or physical defects in any of the pouches. However, in 6 of the 38
transplanted pouches (n=1 for PES and PVDF, n=4 for PVC) a slight opening of
the ends was observed. Examination of the encased macrobeads revealed that in 4
of the 38 transplants (n=2 for PVC and PVDF), broken macrobeads were present.
In all remaining pouches the macrobeads remained intact. Figure 3.3 shows an
opened pouch, containing intact macrobeads.
3.4 Biocompatibility of Materials
Semi-quantitative analysis of the tissue reaction, as documented in figure 3.4,
shows that after 44 days implantation freely dropped PVC membrane pouches had
86.5±6.1% of its surface area free of fibrosis. PVDF and PES pouches had
72.3±6.0 and 72.0±12.7 percent surface area free of fibrosis. Teflon, with
28.7±7.7%, had a smaller amount of surface area free of fibrosis. Individual data,
for each pouch material, including those in which pouches were removed on the
16th day post-implantation or earlier because of death, is listed in Appendix C.
f- l f I..	 F
Tissue reaction, expressed as the percent of surface
area free of fibrosis, for pouches of each material.
PVC (n=6), PVDF (n=7), PES (n=4), PTFE (n=6).
Figure 3.4 Percent of Surface Area Free of Fibrosis After 44 days Implant.
In PVDF, PVC, and PES the majority of fibrosis occurred at the ends of
the pouches. Teflon pouches, on the other hand, experienced fibrous formations
which were evenly spread throughout the total surface area. In one PES and two
PTFE pouches adhesion to the liver occurred. Figure 3.5 shows the tissue
reactions in a PES and a PTFE pouch respectively.
A- PES pouch	 B- MTh pouch
Fibrous Tissue
Figure 3.5 Tissue Reactions of PES and PTFE Pouches (10X)
3.5 Permeability to Insulin
Table 3.2 summarizes the results of insulin release on 1, 7, and 16 days post-
encasement from macrobeads within membrane pouches. Macrobeads encased in
PVC membranes secreted 21.1±6.7 (±SEM), 19.0±4.4, and 11.8±3.1 percent of
their pre-encasement values on 1,7, and 16 days post encasement. Insulin release
from the pouches created with PTFE had mean percents of 20.1±3.9, 38.4±9.6,
28.3±1.9 while PVDF had mean percentages of 95.5±8.9, 83.3±8.1, and 79.2±3.9.
For PES the mean percentages were 107.2±9.8, 106.2±3.3, and 77.2±1.9 on days
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macrobeads was measured on the same days as those which were placed in a
membrane, had 90.4, 91.5, and 104.8 percent of its initial insulin release.
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Table 3.2 Insulin release from Macrobeads before and after















PVC 53.9 9.4 8.4 < 5
PVC 48.3 15.9 13.4 8.7
PVC 123.8 15.9 16.9 10.2
PVDF 75.9 79.1 74.8 58.1
PVDF 27.4 28.5 22.0 23.8
PVDF 59.7 46.8 42.4 44.2
PTEE, 100.1 16.3 29.0 25.9
PTFE 120.6 19.4 34.6 32.4
PTFE 53.3 14.8 30.7 17.2
PES 183.6 228.9 190.8 145.7
PES 252.1 267.9 284.2 198.9
PES 166.2 150.9 169.2 121.9
Control (no encasement) 64.6 58.4 59.1 67.7
CHAPTER 4
DISCUSSION
4.1 Clinical Evaluations after Transplantation
The animal weight data, by showing complete recovery, indicates that all of the tested
materials are non-toxic and, hence, may be considered biomaterials. The weight loss
experienced by recipients of membrane pouches may be attributable to the larger
(5cm), more traumatic incision required to insert the pouches. To insert macrobeads
alone, only a 2cm incision was required. Additionally, because the pouches are larger
than individual macrobeads, subject animals may have initially felt a greater degree of
discomfort upon implantation of a pouch. This discomfort could have magnified
weight loss by affecting the animals' moods and appetites.
41 Effects of 4mm Pore size
The effects observed from transplanting pouches suggests that potentially serious
complications may arise from dropping large pore pouches freely into the peritoneal
cavity. As designed for this study, the tubular pouches were rigid, nonflexible
devices. Upon intra-abdominal pressures, these devices allowed penetration of
intestinal tissue through the 4mm. pores. In rats, therefore, large pore pouches are not
suitable. A possible solution may be to reduce the pore size.
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4.3 Durability of Pouches
The strength of the membrane pouches is an important factor in designing a mode of
delivery for macrobead transplantation. Within the peritoneal cavity the pouches will
encounter both direct and shearing forces. Examinations of the retrieved pouches
indicate that all four materials have strength sufficient enough to allow for
intraperitoneal implantation. The opening at the ends of several pouches suggests
that either an inadequate amount of glue was added or that the Milipore MF cement
glue was not effective in properly sealing the end of the pouch. Alternative methods
of closure, e.g. stitching or stapling, should be investigated. To prevent crushing and
breaking of macrobeads, when encased in a semi-tubular pouch, it may be necessary
to suspend the beads in an agarose gel matrix. The matrix, in addition to providing
support, may increase the efficiency of the mode of delivery by preventing dead
space, e.g. air bubbles from forming adjacent to the macrobeads.
4.4 Biocompatibility of Materials
Analysis of tissue reaction suggests that PVC, PVDF, and PES membranes may be
suitable materials for intra-peritoneal transplantation. Fibrosis at the ends of these
pouches was minimal and hence should not affect the functioning abilities of encased
macrobeads. The adhesion of freely dropped pouches to the liver, however, is a
serious concern that must be addressed. To minimize the possibility of adhesions and
abscess formations Lanza has suggested localizing devices in a specific place [38]. A
pouch for example, could be immobilized against the peritoneal wall.
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4.5 Permeability to Insulin
The insulin release data shows that PVDF and PES membranes are more permeable to
insulin than PVC and PTFE membranes. The data obtained for PVC membranes is
surprising because this material has been used by researchers for islet transplantation
[38,39]. Pores, for the PVC membranes used in this study, had a molecular weight
cutoff of 50,000 daltons. Insulin has a molecular weight of 6,000 daltons, and so
should easily pass through. Through communications with Amicon Inc., the
manufacturers of PVC membranes, a probable explanation for our results was
derived. PVC membrane filters, unlike the PVC hollow fibers used by other
investigators, have an inert glossy coating on one side. This coating, described as the
`skin' of the membrane, allows for one directional flow. In our PVC pouches, the
skin remained on the outside, i.e. the side exposed to the medium. Hence, glucose
and nutrients in the medium were able to enter the pouch and nourish the islets.
However, because of the one way flow, very little insulin produced by the islets was
able to cross the membrane and enter into the medium.
The reduction of insulin release from macrobeads when encased in PTEE
pouches can most likely be attributed to the membrane's hydrophobicity. Transport
of glucose and other nutrients into the pouch, as well as diffusion of insulin out of the
pouches depends upon the hydrophilic properties of the material. Hydrophilic
membranes, by absorbing the medium, would be more conducive to insulin and
glucose transport.
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4.6 Phase I & II Summary
In Phases I & II, pouches of each material underwent design, durability,
biocompatibility, and permeability examinations. The results have provided insights
for designing a mode of delivery for macrobead transplantation.
By comparing the materials to each of the above parameters, PVDF and PES
membranes seem to be superior for intraperitoneal transplantation. Their qualities of
durability and biocompatibility indicate that they would be able to remain implanted
in the peritoneal cavity for an extended period of time. Permeability tests show that
when exposed to glucose, macrobeads encased in either of these two membranes will
be able to respond.
CHAPTER 5
CONCLUSIONS
5.1 Materials for Pouches
In designing a mode of delivery for macrobead transplantation, four materials were
tested. Based upon the results, two materials: Polyethersulfone (PES) and
Polyvinylidenedifluoride (PVDF) appear suitable for encasing a large number of
macrobeads. If the permeability of PVC membrane filters can be modified to allow
unhindered flow in both directions, then it also may be suitable for macrobead
encasement.
It is important to note here, that only four materials were tested.
Investigations of other commercially available biomaterials may find a more
promising candidate. Polyvinyl alcohol and Polyacrylonitrile are two additional
materials which have been cited in the literature for biocompatibility and selective
permeability [35,45,46]. In 1992, Mahgoub reported the ability to achieve
euglycemia in diabetic Wistar Furth rats by transplanting xenogenic islets which were
encased in rat amniotic membranes [47]. If similar results using xenogenic amniotic
membranes can be demonstrated, then placement of macrobeads into such membranes
may also be a possibility.
Physiochemical treatments, which modify a specific property, is an additional
method which can be used to improve the efficacy of existing membranes. For
example, the electrical discharges of the Corona Surface Treatment has been shown to
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improve the insulin permeability of acrylonitrile membranes [48]. Utilization of such
physiochemical treatments may allow the consideration of what otherwise would be
non-useful materials.
5.2 Pouch Design
The pouches designed for this study were rigid semi-tubular devices. PES, PVC and
PVDF pouches experienced fibrosis at the ends where the surface was rough and
tactile. Clearly, to avoid such tissue reactions, the device must be smooth throughout
the entire surface area. Redesigning the pouch either so it is more flexible, or so it
can be immobilized against the peritoneal wall may prove effective in preventing
fibrotic and adhesive formations. A flexible pouch, like a fishing net which would
yield and change shape when exposed to pressure, could be created by crosslinking a
pliable fiber material into a type of crochet mesh [49]. Thin PES hollow fibers are
commercially available.
Figure 5.1 shows a hypothetical design for immobilizing a macrobead-pouch
graft against the peritoneal wall. Through immobilization, contact between the pouch
and peritoneal organs can be limited.
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a- Peritoneal Wall 	 b- Membrane Pouch
- Insertion of Macrobead into Membrane Pouch
Figure 5.1 Immobilizing a pouch against the Peritoneal Wall
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5.3 Future Experiments
In this study, potential materials and preliminary methods to evaluate these materials
for macrobead transplantation have been described. The next step is to design
protocols which, in greater detail, study a pouche's biocompatibility and permeability.
In assessing biocompatibility, we semi-quantitatively determined the degree of
tissue reaction on the pouche's outer surface. This gave us a general description on
the material's compatibility. However, in order to thoroughly evaluate a material, an
understanding of the reactions occurring at the tissue-material interface should be
obtained. Histological examinations of retrieved pouches could tell us what is
happening on the membrane's surface. It would be interesting to see whether the
membrane's pores remain open or become clogged after intraperitoneal
transplantation. Experiments in which sections of retrieved pouches are subjected to
histological examinations should be conducted before any conclusive assessment on
the material is made.
To determine the permeability to insulin, 6-10 porcine macrobeads were
inserted, in single-file fashion, into pouches of each material. The results showed that
for two materials, there was no reduction in insulin secretion from the macrobeads.
For transplantation into large animals a greater number of macrobeads will be
required. As a result, placement of macrobeads in single-file fashion may not be
possible. A pouch which maintains macrobeads in multiple, adjacent columns may be
required. However, because transport into and out of the macrobeads is based on
diffusion with the surrounding environment, the beads located in the center of such a
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design may not be able to function as they normally would. The ability of these beads
to assess glucose concentrations and then respond with insulin secretions might be
affected by the functioning of adjacent macrobeads. Figure 5.2 graphically explains
this potential phenomena. In vitro experiments in which a hypothetical
transplantation number of macrobeads are placed into a pouch and then assayed for
insulin release should be performed. Additionally to assess their response abilities,
these pouches should be challenged with varying concentrations of glucose.
Ultimately, the efficacy of a mode of delivery for macrobeads will be
determined by performing transplantations into diabetic recipients. Experiments in
which macrobead-pouch grafts are compared to controls of unencased macrobeads,
non-transplanted diabetic animals, and non-transplanted normal recipients should first
be performed. Body weight, blood glucose levels, blood c-peptide levels, and
response to glucose tolerance tests are parameters to be measured. To assess whether
immobilization of a device is effective in preventing adhesions, transplantations into
large animal models (e.g. rabbits, cats, and dogs) should be performed.
-Jo direction of insulin release from adjacent macrobeads
The macrobead, in the center of the pouch might, because of
secretion from adjacent macrobeads, sense high insulin levels.
Hence it will not secrete any insulin. As a result, the net insulin
release from the pouch may be less than the sum of insulin
release from the individual macrobeads.
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Figure 5.2 Placement of Macrobeads into pouch
APPENDIX
A- PORCINE INSULIN RIA
B- INDIVIDUAL ANIMAL WEIGHT DATA







PORCINE INSULIN RIA KIT •
250 TUBES
Reagents Supplied
This insulin assay has been developed for the measiwnent of porcine insulin in plasma or serum. The
tracer is prepared with human insulin. All reagents ngv.ready for use Refrigerate upon arrival.
1 i Assay buffer (0.05M Phosphosaline pH 7.4 containing 0.025M EDTA, 0.01% EMTSA and 1%
BSA), 40 ml.
2. Insulin Antibody, 26 ml.
3. 125 i-insulin Label. Hydrate using entire contents (27 ml) of label hydrating buffer."•-
4. Label Hydrating Buffer (containing normal guinea pig lgG as a carrier). 1251-Insulin must belridrated
with entire contents of label hydrating buffer. ••: .
5. Human Insulin Standards, 2 ml each
2, 5, 10, 20, 50, 00, 200 p.U/m1
6. Quality Controls I (low) and II (high), 2 ml each
7. Precipitating Reagent, 260 mi.
Use Borosilicate glass tubes (12 x 75 mm) for assay procedure.
Assay Set-up •
1. Pipette 300 pl of assay buffer to the non-specific binding (NSB) tubes (3-4)
and 200 pl of buffer to reference (Bo) tubes (5-6) and add 100 pl of buffer to tube 7 to end of assay.
2. Pipette 100 pi of standards and quality controls In duplicate. (see Contents of Tubes).
.
4) Pipet 100 pi of sample in duplicate. (NOTE: when smaller volumes of sample are used, additionalbuffer should be added to compensate for difference so that volume is equivalent to 100 p1, e.g.
when using 50 pi sample, add 50 pi buffer).
4. Pipette 100 pi of 125 1- insulin to all tubes.
5. Pipette .100 p1 of porcine antibody to all tubes except totals (1-2) and NSB (3-4).
6. Vortex, cover and incubate overnight (18-24 hours) at 4°C.
LINCO RESEARCH, INC. • 14 Research Park Dr. • St Charles, MO 63304
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7. Add 1.0 ml of precipitating reagent to all tubes (except totals).
8. Vortex and incubate 20 minutes at 4° C.
10. 	 Decant supernatant, drain tubes for 1 minute, and count pellet.
Contents of Tubes/Assay Procedure Chart -
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9. 	 Centrifuge for 15 minutes at 2,000-3,000 x g 2 	 e S. f
•
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The calculations for insulin can be automatically performed by a gamma counter with data reduction
system. The log of the known concentration (standards) is plotted as X versus the logit B/REF [unknown
bound counts/zero standard bound counts (B/Bo)] plotted as Y. The log/loglt function is used to linearize
the curve by five cycle weighted regression analysis. Results are reported as RU/mi Insulin of unknown
sample. [NOTE: When sample volumes assayed differ from 100 an appropriate mathematical
adjustment must be made to accommodate for the dilution factor (e.g. If 50 of sample is used, then
calculated data must be multiplied by 2)].
Manual Calculation
1. Average duplicate counts for NSB (tubes 1,2), Total Counts (tubes 3,4) and Total Binding (tubes 5,6), •
and remaining samples.
2. Subtract the average NSB counts from each average count (except for Total Counts). These are the 	 -
counts used in the following calculations.
• 3. Calculate the percentage of tracer bound [(Total Binding Counts/Total Counts) x 100]. This should be
35-40%. 	 • •
4. Calculate the percentage of maximum binding (%B/BO) for each standard and sample [%B./B0
(Sample or Standard/Total Binding) x 1001.
5. Plot the % MO for each standard on the y-axis and the known concentration of the standard on the x-, 	 . 	 •
axis. The use of log-log graph paper will result in a nearly linear curve. 	 •
6. Construct the reference curve by joining the points with a smooth curve.
7. Determine the Insulin of the unknown samples (unknowns and controls) by interpolation of the
reference curve.
Limits of Test Procedure
1. Assay should be rejected if one of the two QCs falls outside of 2 SDs.
See the supervisor.
2. If the difference between duplicate results of a sample is >10% CV, repeat the sample.
3. The limit of sensitivity for the insulin assay is 211U/m1 (100 RI sample size).
4. The limit of linearity for the insulin assay is 200 p.U/m1 (100 IA sample size). Any result gmater than 200
µU/ml should be repeated on dilution using assay buffer as a diluent.
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Appendix A (Continued)
Interpretation
Normal Fasting Range: 5-15 pli/m1
Performance
ED80 . 7 ± 1 gU/m1
ED50 = 29 ± 2 gU/m1
ED20 = 122 ± 11 pU/mi
Crossreactivity
Porcine Insulin 	 100%
Human Insulin 	 100%
Human Proinsulin 	 38%
Des 31,32 	 47%
Des 64, 65 	 72%
Glucagon 	 Not Detectable
Somatostatin 	 Not Detectable
Pancreatic Polypeptide 	 Not Detectable
References
1. Morgan, CR and Lazarow, A. Immunoassay of insulin: Two antibody system. Plasma Insulin levels In
normal and diabetic rats. Diabetes 12:115, 1963.
Reference date: 10/15/92
Replacement Reagents 	 Cat. #
1. Assay Buffer 	 AB -P
2, Porcine Insulin Antibody 	 1012-K
3. 1251-Insulin, with label hydrating buffer 	 9011-K
4. Human insulin Standards 	 8012-K
5. Quality Controls 	 6000
6. Precipitating Reagent 	 PR-UV
Signatu
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Animal Day Post Tx weight % of zero wt. Animal Day Post Tx weight % of zero wt.
41-0 0 207.5 100% 41-1R 0 216.4 100%
4 185.3 89% 4 196.1 91%
8 215.5 104% 8 232.1 107%
12 228.9 110% 12 241.3  112%
16 238.3 115% 16 255 118%
20 254.3 123% 20 280.3 130%
24 256 123% 24 282.5 131 %
28 264.8 128% 28 298.3 138%
32 264.8 128% 32 291.9 135%
36 270.3 130% 36 301.2 139%
40 274.8 132% 40 305.4 141%
44 282.6 136% 44 310.8 144%
26-1L 0 200.8 100% 27-0 0 237.2 100%
4 193 96% 4 224.8 95%
8 211.7 105% 8 238.2 100%
12 224.3 112% 12 247.6 104%
16 232.7 116% 16 259.1 109%
20 244.2 122% 20 263.3 111°/
24 255.6 127% 24 268.4 113%
28 265.6 132% 28 284.3 120%
32 275.6 137% 32 285.3 120%
36 280.5 140% 36 283.9 120%
40 286.1 142% 40 295.9 125%
44 287.6 143% 44 292.4 123%
30-1L 0 207.6 100% 26-1R 0 212.7 100%
4 195 94% 4 203.6 96%
8 212.5 102% 8 218.3 103%
12 229.3 110% 12 234.1 110%
16 245.5 118% 16 239.6 113%
20 255.7 123% • 20 245.1 115%
24 r 	 272.3 131% 24 258.5 122%
28 277.1 133% 28 265.3 125%
32 283.2 136% 32 273.1 128%
36 298.9 144% 36 278.6 131%
40 298.8 144% 40 280.9 r 	132%
44 1- 	 306.7 148% 44 283.1 133%
39-1L 0 r 	 204.5 39-0 0 215.9 r
4 191.4 4 195
8 227. 6 8 228.6
_ 12 234.6 12 241.9
16 243.5 16 239.5
39-1R 0 222.8 41-1L 0 198.2
4  206.6 4 144
8 237.4 DIED




Animal Day Post Tx weight % of zero wt. Animal ... Day Post Tx weight % of zero wt.
35-0 0 206.7 100% 34-0 0 195.2 100%
4 192.7 93% 4 176.9 91%
8 203.5 98% 	 ____ 8 191.1 98%
12 221.8 107% 12 214.9 110%
16 	 _ 236.6 114% 16 221.1 113%
20 248.3 120% 20 237.2 122%
24 263.7 128% 	 i 24 252.6 129%
28 266.1 129% 28 257.4 132%
32 269.4 130% 32 258.6 132%
36 275.5 133% 36  264.2 135%
40 273.6 132%_ 40 260.3 133%
44 284.2 137% 44 271.4 139%
34-1R 0 195.5 100% 28-1R 0 226.4 100%
4 184.9 95% 4 - 215.1 95%
8 191.3 98% 8 228.8 101%
12 211.4 108% 12 240.8 106%
16 217.8 111% 16 256.1 113%
20 228.1 117% 20 257.7 114%
24 241.6 124% 24 261.8 116%
28 248.9 127% 28 269.9 119%
32 250.7 128% 32 270.4 119%
36 259.4 133% 36 	 T 271.6 120%
40 257.9 132% 40 275.9 122%
44 268.8 137% 44 274.5 121%
22-2R 0 210.5 100% 22-1L 0 198.3 100%
4 173.1 82% 4 174.9 88%
8 179.6 85% 8 175.1 88%
12 185.3 88% 12 197.7 100%
16 187.3 89% 16 213.3 108%
20 196.3 93% 20 229.7 116%
24 216 103% 24 237.2 120%
28 224.4 107% 28 244.9 123%
32 239.9 114% 32 252.9 128%
36 249.7 119% 36 263.9 133%
40 256.2 122% 40 265.5 134%
44 263 r 125% 44 i 	 269.2 136%
27-1R 0 201.6 100% 37-1R 0 202.9
4 193.1 96% 4 190.7
8 209.6 104% 8 202.3
12 220.5 109% 12 221.7
16 233.8 116% 16 234.2
20 240.3 119% 37-0 0 202.7
24 255.2 127% 4 185.9
8 199.6
. 	 •••■•■■■•
32 266.2 132% 12 223.3
36 272.6 135% 16 243.6
40 277.5 138% 35-1R 0 201.2
44 282.3 140% 4 186.2
8 203.6
12 222.9 •




Animal Day Post Tx weight % of zero wt. Animal Day Post Tx weight % of zero wt.
29-0 0 210.8 100% 43-0 0 203.3 100%
4 209.3 	 : 99% 4 185.6 91%
8 215 102% 8 215 106%
12 224.4 106% 12 228.8 113%
16 235.2 112% 16 239 118%
20 241.8 115% 20 259.5 128%
24  252.7 120% 24 264.1 130%
28 258.6 123% 28 275.1 135%
32 262.9 125% 32 275.7 136%
36 261.7 124% 36 283.3 139%
40 242.3 115% 40 291.2 143%
44 203.6 97% 44 299.4 147%
43-1R 0 199.5 100% 44-1R 0 205.6 100%
4 175.4 88% 4 190.3 93%
8 198.5 99% 8 217.8  106%
_ 12 213.8 107% 12 230.1  112%
16 225.9 113% 16 237.8 116%
20 241.6 121% 20 255.4 124%
24 239.3 120% 24 255.9 124%
28 249.3 125% 28 264.4 129%
32 247.9 124% 32 263.2 128%
36 258.3  129% 36 273.9 133%
40 264.5 133% 40 277.4 135%
44 275.9 ' 	 138% 44 1 	 281.1 137%
30-1R 0
'
202.9 25-1L 0 211.6
4 174.8 172.4
DIED 8 DIED
25-1R 0 217.7 36-0 0 210.1
4 186.2 4 181.2
8 204.9
12 223.2
1 	 i I 16 239.5
44-0 0 214.7 I 	 36-1R 0 212.2
4 - 191.8 4 187.3
8 1 	 212.3 8 213.1
12 222.3 4 12 223.8
16 239A 16 239.2
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Appendix C- Percent Fibrosis Free Data
Material (animal)























% Free of Fibrosis after 44 days
of implantation
PES (43-0) 96.4






















Example Calculation: PTFE (41-1R)
Pouch Length: 4.8cm 	 Pouch Width: 3cm
Total Surface Area: 4.8cm X 3cm = 14.4cm 2 (simplify into rectangular shape)
Radius of Large Pores: .2cm
Area of each Pore (icr2): 00(.2)2 = .13cm2
Number of Large Pores NOT  covered with fibrosis: 3
Surface Area Free of Fibrosis: lcm x 3cm = 3cm 2
+ 3(.13cm2) = .38cm2
3.4cm2
Percent Free of Fibrosis: (3.4cm 2/ 14.4cm2) x 100 = 23.6% 
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